Evidence Dose
← All articles Supplements

Omega-3 Forms: Which to Buy for Blood Levels vs Outcomes

· 11 min · omega-3 forms compared
Dr Cath
Chemistry PhD · evidence-based supplementation
How I read the evidence →
Omega-3 Forms: Which to Buy for Blood Levels vs Outcomes

Which omega-3 form should you buy: ethyl ester, triglyceride, or krill?

If your only concern is getting EPA and DHA into your blood, the triglyceride and re-esterified triglyceride forms are absorbed somewhat more efficiently than the ethyl ester per milligram, and krill oil delivers its omega-3 attached to phospholipids rather than glycerol. But that absorption gap is the smaller story. The larger one is that the direction of the answer changes completely depending on whether you are chasing a blood-level number or a clinical outcome – and on those two questions, the forms do not line up the way the labels imply. Read the criterion before you read the price.

What are you actually comparing?

All three products deliver the same two active molecules: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). What differs is the chemical scaffold those fatty acids are attached to before you swallow them.

  • Triglyceride (TG) and re-esterified triglyceride (rTG) – the fatty acids sit on a glycerol backbone, the form found in fish. rTG is TG that was broken down to concentrate the EPA/DHA and then rebuilt onto glycerol.
  • Ethyl ester (EE) – the fatty acid is bonded to an ethanol group instead of glycerol. This is the form produced when fish oil is concentrated; it is cheaper to manufacture at high purity and is the basis of most prescription-grade products.
  • Krill oil – the EPA and DHA are carried largely on phospholipids rather than triglycerides, plus a small amount of the antioxidant astaxanthin. Krill products are typically lower in total EPA/DHA per capsule.

"Ethyl ester" is not a marketing downgrade of the same oil. It is a genuinely different molecule that your gut has to process differently, which is exactly why absorption studies find a gap. But a different scaffold is not automatically a different clinical result, and that distinction is where most of the confusion lives.

What decides the choice, in order of weight

Three criteria carry almost all the decision, and they are not equally important:

  1. What clinical outcome, if any, you are buying (heaviest weight). Lowering triglycerides is an intermediate outcome. Preventing a heart attack is a clinically meaningful one. These are separate tiers of evidence and the forms behave differently across them.
  2. Blood EPA/DHA delivered per dose (moderate weight). This is a biomarker – a real and measurable one – but it is a surrogate, not a health outcome in itself.
  3. Cost per gram of actual EPA/DHA (real, but subordinate). The headline milligram figure on the label is total oil in some products and total EPA/DHA in others; the number that matters is grams of EPA/DHA, priced.

A criterion many readers arrive with that matters less than they expect: the "natural triglyceride form" claim. It is chemically true that TG resembles dietary fish oil more closely than EE does. Whether that closeness produces a better clinical result in you is a different question, and it has not been settled by a head-to-head trial measuring outcomes.

Do these three forms even share an evidence base?

Most comparisons skip this question, and skipping it is how a form gets credited with evidence it never earned.

They share a partial evidence base, because they share the same active molecules – but the large outcome trials were run on specific formulations, and the results do not transfer cleanly between them. Consider what the major cardiovascular trials actually used:

  • The trial of a highly purified EPA ethyl ester (icosapent ethyl) in people with elevated triglycerides on statin therapy reported a reduction in ischaemic cardiovascular events. That result belongs to that molecule, that dose, and that population – not to "ethyl esters" as a category, and not to fish oil generally.
  • A separate large trial of a carboxylic-acid EPA/DHA formulation against a corn-oil comparator, in a high-cardiovascular-risk population, found no reduction in major adverse cardiovascular events despite favourable changes in lipid and inflammatory markers. Same class of molecules, different formulation and EPA:DHA mix, opposite headline result.

Two things follow. First, two independent placebo- or comparator-controlled trials cannot be added together to rank one form above another; they were different molecules, doses and comparators. Second, and more importantly for a shopper: neither of those trials tested an over-the-counter triglyceride fish oil capsule or a krill capsule. No published head-to-head trial has compared ethyl ester versus triglyceride versus krill oil for a clinical outcome in the same participants. Any ranking on outcomes is therefore not available from the data – only from mechanism, and mechanism is not the same tier.

What each form actually shows

Ethyl ester

What it is: EPA and/or DHA on an ethanol backbone; the form behind most concentrated and prescription-grade products.

What was shown: The strongest clinical outcome evidence for any single omega-3 product sits with a purified EPA ethyl ester at a high dose in statin-treated patients with high triglycerides, which reduced ischaemic events. That is a clinically meaningful outcome, but it is narrow – a specific molecule, a specific patient group. Absorption research consistently finds ethyl esters are taken up less efficiently than triglyceride forms. In a comparison of concentrated preparations in 72 volunteers taking roughly 3.3 g of EPA plus DHA daily for two weeks, uptake from re-esterified triglycerides ran at 124% of natural fish oil, while ethyl esters reached 73%.

Who it may suit: People whose goal is triglyceride lowering under medical supervision, where the concentrated, well-characterised form is what the outcome data actually studied.

Triglyceride and re-esterified triglyceride

What it is: EPA/DHA on a glycerol backbone; rTG is a concentrated, rebuilt version.

What was shown: Better absorption per milligram than ethyl ester is well supported at the biomarker level. A 2025 review of human bioavailability data ranks the forms free fatty acids, then phospholipids, then re-esterified triglycerides, then unmodified triglycerides, with ethyl esters last — and adds that differences measured after a single dose usually fail to persist in long-term supplementation studies, which is how these products are actually taken. That is a surrogate endpoint. There is no dedicated large outcome trial establishing that this absorption advantage translates into fewer cardiovascular events versus ethyl ester in the same people.

Who it may suit: People optimising their blood omega-3 level who value absorption efficiency and are willing to pay for it, and who accept that the endpoint they are buying is a biomarker rather than a demonstrated outcome.

Krill oil

What it is: EPA/DHA carried mainly on phospholipids, with astaxanthin; typically lower EPA/DHA content per capsule.

What was shown: The phospholipid delivery is a genuine mechanistic difference, and absorption data favour it: in a crossover trial in 24 healthy adults, four weeks of 600 mg of n-3 fatty acids daily from krill oil raised the red-cell omega-3 index more than the same dose from fish oil. But krill oil was not the intervention in the major cardiovascular outcome trials, and its lower EPA/DHA density means matching the doses used in triglyceride-lowering research often requires many capsules. The clinical-outcome evidence specific to krill oil is thin.

Who it may suit: People who tolerate it better than fish oil, or who prefer smaller doses, and who treat the phospholipid and astaxanthin claims as mechanistic rather than proven benefits.

What the whole-supplement literature says, across forms

Step back from the form question and the effect sizes shrink. The most extensive systematic review of the field, pooling 86 randomised trials in more than 160,000 adults, concluded that increasing long-chain omega-3 intake slightly reduces the risk of coronary heart disease mortality and coronary events, and reduces serum triglycerides — while making little or no difference to all-cause mortality, cardiovascular mortality or stroke. "Slightly" is the review's own word, and the certainty of that evidence is rated moderate to low. This covers supplementation broadly rather than any one form, and it is the backdrop against which the two divergent trials above should be read: one purified high-dose EPA product moved a composite of ischaemic events, one carboxylic-acid formulation did not, and the pooled average across everything else is a small effect on a narrow set of endpoints.

For the specific goal of lowering triglycerides, the effect is more consistent. Research in people with type 2 diabetes and high triglycerides found that omega-3 fatty acids reduced triglycerides, though the size of the reduction varied between individuals. Triglyceride lowering is real; it is an intermediate outcome, and a triglyceride number falling is not the same as an event prevented.

Sorting the differences that matter from the ones that don't

  • Demonstrated and outcome-changing: A single, highly purified high-dose EPA ethyl ester product reduced ischaemic events in a defined high-risk group. This does not generalise to the category or to general prevention.
  • Demonstrated but a matter of biomarker, comfort or price: Triglyceride and krill forms raise blood omega-3 more efficiently per milligram than ethyl ester. Real, measurable, and about a surrogate – not a proven outcome advantage.
  • Claimed but unverified for outcomes: "Natural triglyceride form is better," "phospholipid delivery is superior," "astaxanthin adds cardiovascular protection." These are mechanistic or biomarker claims marketed as clinical superiority. No head-to-head outcome trial supports ranking the forms against each other.

Who should choose differently

If you are on a statin with high triglycerides and managing cardiovascular risk, the form with actual outcome data behind it is the purified high-dose EPA product, and that is a conversation with your doctor, not a supplement-aisle decision – the trial was run on a prescription-grade formulation and dose. If you simply want to raise a low blood omega-3 index and cost is secondary, a triglyceride or rTG form absorbs more efficiently. If you tolerate fish oil poorly or want a smaller dose and accept a thinner evidence base, krill is defensible. And if your goal is general cardiovascular prevention with no elevated triglycerides, the pooled evidence points to a small benefit on coronary endpoints from long-chain omega-3 intake as such — a benefit no individual form has been shown to own.

Verdict: settleable on blood levels, not on outcomes

On the biomarker question – which form raises blood EPA/DHA most efficiently per milligram – the answer leans toward the triglyceride and phospholipid forms over the ethyl ester, and that is supported by absorption data. On the question the marketing actually implies – which form is better for your health – the comparison is not settleable on current data, because the head-to-head outcome trial across these three forms does not exist. The one place a clinical outcome was demonstrated belongs to a specific purified ethyl ester at a specific dose in a specific population, and it neither promotes ethyl esters as a class nor transfers to the capsule you would buy off a shelf.

The practical rule to carry to the next label: decide first whether you are buying a blood number or a clinical outcome, then price the product by grams of EPA/DHA rather than by total oil or by the form named on the front. Do not let a well-supported absorption figure be sold to you as a health result it was never measured against.

Sources

Popular articles

Content on this site is for informational and educational purposes only and is not medical advice. Consult a physician or pharmacist before starting any supplementation.

Contents